SAB Biotherapeutics (SABS) Equity Average: 2021-2025
Historic Equity Average for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $88.5 million.
- SAB Biotherapeutics' Equity Average rose 113.30% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.5 million, marking a year-over-year increase of 113.30%. This contributed to the annual value of $41.6 million for FY2024, which is 5.76% down from last year.
- As of Q3 2025, SAB Biotherapeutics' Equity Average stood at $88.5 million, which was up 429.84% from $16.7 million recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' Equity Average peaked at $88.5 million during Q3 2025, and registered a low of $16.7 million during Q2 2025.
- In the last 3 years, SAB Biotherapeutics' Equity Average had a median value of $31.4 million in 2024 and averaged $37.3 million.
- In the last 5 years, SAB Biotherapeutics' Equity Average soared by 137.39% in 2024 and then crashed by 66.22% in 2025.
- SAB Biotherapeutics' Equity Average (Quarterly) stood at $36.8 million in 2021, then dropped by 16.23% to $30.8 million in 2022, then climbed by 17.63% to $36.3 million in 2023, then decreased by 13.35% to $31.4 million in 2024, then surged by 113.30% to $88.5 million in 2025.
- Its last three reported values are $88.5 million in Q3 2025, $16.7 million for Q2 2025, and $23.7 million during Q1 2025.